2211175-99-2
Chemical Structure
LCB-2151
- CAS No.: 2211175-99-2
- Formula:C37H43F8N3O5S2
- Molecular Weight:825.87
IUPAC Name: (R)-N-(1-((2R,4R,5S)-3,3-difluoro-4,5-bis(hydroxymethyl)-4-methyltetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)-3,3-dimethyl-6,8-bis((4-(trifluoromethyl)benzyl)thio)octanamide
InChIKey: XZWVKRKEAAGVCH-ZSBXFVPVSA-N
SMILES: OC[C@@]1(C)C(F)(F)[C@H](N2C(N=C(NC(CC(C)(C)CC[C@@H](SCC3=CC=C(C(F)(F)F)C=C3)CCSCC4=CC=C(C(F)(F)F)C=C4)=O)C=C2)=O)O[C@@H]1CO
Biological Activity: LCB-2151 (Compound 2), a nucleoside analogue, is an anticancer agent. LCB-2151 disrupts the two primary sources of ATP production (glycolysis and mitochondrial oxidative phosphorylation), reducing the bioenergetic capacity of KRAS-mutated pancreatic cancer cells and inducing ROS formation. LCB-2151 effectively inhibits key enzymes (such as CACT and CPT2) in glycolysis, the TCA cycle and fatty acid β-oxidation. LCB-2151 has significant cytotoxicity and induces cells apoptosis. LCB-2151 can be used for radiation therapy of cancers research[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
LCB-2151 | LCB-2151 (Compound 2), a nucleoside analogue, is an anticancer agent. LCB-2151 disrupts the two primary sources of ATP production (glycolysis and mitochondrial oxidative phosphorylation), reducing the bioenergetic capacity of KRAS-mutated pancreatic cancer cells and inducing ROS formation. LCB-2151 effectively inhibits key enzymes (such as CACT and CPT2) in glycolysis, the TCA cycle and fatty acid β-oxidation. LCB-2151 has significant cytotoxicity and induces cells apoptosis. LCB-2151 can be used for radiation therapy of cancers research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
